TXA: Rx that Breaks My Heart

Tranexamic acid is an antifibrinolytic, not a pro-coagulant, and its value in emergency care depends heavily on the bleeding syndrome in front of you. Trauma hemorrhage, postpartum hemorrhage, and non-massive hemoptysis are the strongest ED use cases; GI bleeding is the clearest place to avoid it.

Where TXA Helps Most

• Trauma hemorrhage benefit: Major traumatic bleeding is the cleanest indication: early TXA lowers mortality, with CRASH-2 showing about a 1.5% absolute reduction when given within 3 hours.
• Postpartum hemorrhage signal: Postpartum hemorrhage has the best obstetric evidence, with the WOMAN trial showing roughly a 30% reduction in death from bleeding when treatment is early.
• Pediatric trauma support: Pediatric major hemorrhage trends the same direction as adults, with PED-TRAX suggesting lower mortality and little signal for harm in severe trauma.
• Non-massive hemoptysis niche: Nebulized TXA can shorten bleeding duration and may prevent progression to massive hemoptysis, a practical distinction we get into in the episode.

Where TXA Might Help

• Atraumatic ICH uncertainty: In spontaneous intracranial hemorrhage, TXA has shown less hematoma expansion and early survival signal without clear long-term functional benefit.
• Subarachnoid hemorrhage context: Aneurysmal subarachnoid hemorrhage is more nuanced: TXA looks more plausible when definitive aneurysm care is delayed, rather than readily available.
• Epistaxis mixed evidence: Epistaxis data are conflicting; earlier trials were encouraging, but the NoPAC trial found no reduction in transfusion need or recurrent bleeding.
• Post-tonsillectomy and dental use: Post-tonsillectomy hemorrhage and dental bleeding have small, low-quality signals of benefit, especially with local application and pressure, but not definitive proof.

Where TXA Underperforms

• GI bleed harms: Acute GI bleeding has moved from maybe to no: HALT-IT showed no mortality benefit and higher risks of venous thromboembolism and seizures.
• Angioedema weak rationale: Despite a mechanistic appeal in hereditary angioedema, case-level evidence has not shown meaningful clinical benefit for TXA in the ED setting.
• Risk profile reminder: TXA is inexpensive and generally available, but seizure risk and thrombosis concerns matter most when the evidence for benefit is thin or absent.
• Bedside yes-maybe-no frame: A simple mental model helps: yes for trauma, postpartum hemorrhage, and non-massive hemoptysis; maybe for select focal bleeds; no for GI bleed. We lay out the practical boundaries in the chapter.

References:

1. Roberts I, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1-79. PMID: 23477634
2. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial [published correction appears in Lancet. 2017 May 27;389(10084):2104]. Lancet. 2017;389(10084):2105-2116. PMID: 28456509
3. CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial [published correction appears in Lancet. 2019 Nov 9;394(10210):1712]. Lancet. 2019;394(10210):1713-1723. PMID: 31623894
4. Fakharian E, Abedzadeh-Kalahroudi M, Atoof F. Effect of Tranexamic Acid on Prevention of Hemorrhagic Mass Growth in Patients with Traumatic Brain Injury. World Neurosurg. 2018;109:e748-e753. PMID: 29074420
5. Bossers SM, et al. Association Between Prehospital Tranexamic Acid Administration and Outcomes of Severe Traumatic Brain Injury. JAMA Neurol. 2021;78(3):338-345. PMID: 33284310
6. Rowell SE, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury [published correction appears in JAMA. 2020 Oct 27;324(16):1683]. JAMA. 2020;324(10):961-974. PMID: 32897344
7. Post R, et al. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet. 2021;397(10269):112-118. PMID: 33357465
8. Akkan S, et al. Evaluating Effectiveness of Nasal Compression With Tranexamic Acid Compared With Simple Nasal Compression and Merocel Packing: A Randomized Controlled Trial. Ann Emerg Med. 2019;74(1):72-78. PMID: 31080025
9. Reuben A, et al. The Use of Tranexamic Acid to Reduce the Need for Nasal Packing in Epistaxis (NoPAC): Randomized Controlled Trial. Ann Emerg Med. 2021;77(6):631-640. PMID: 33612282
10. Schwarz W, et al. Nebulized Tranexamic Acid Use for Pediatric Secondary Post-Tonsillectomy Hemorrhage. Ann Emerg Med. 2019;73(3):269-271. PMID: 30292524
11. Wand O, et al. Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial. Chest. 2018;154(6):1379-1384. PMID: 30321510
12. HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10241):1927-1936. PMID: 32563378
13. Eckert MJ, et al. Tranexamic acid administration to pediatric trauma patients in a combat setting: the pediatric trauma and tranexamic acid study (PED-TRAX). J Trauma Acute Care Surg. 2014;77(6):852-858. PMID: 25423534